A new survey commissioned by Leo Pharma confirms there’s plenty of room in the market for its chronic hand eczema treatment ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup ...

Sixty-five percent of dermatology providers surveyed agree there is a lack of education and understanding of chronic hand ...

Gilead Sciences and LEO Pharma have entered a strategic collaboration to expedite the development and commercialisation of the latter’s small molecule oral signal transducer and activator of ...

Danish dermatology specialist LEO Pharma could be just weeks away from EU approval for delgocitinib, a treatment for chronic hand eczema (CHE) considered to be its top pipeline prospect.

Shanghai Junshi Biosciences and its subsidiary TopAlliance Biosciences are set to enter a collaboration with LEO Pharma to distribute and market the monoclonal antibody, toripalimab, in Europe.

Researchers have found in DELTA China trial that delgocitinib cream (Anzupgo) 20 mg/g significantly reduces severity of ...

LEO Pharma will host a symposium, “Chronic Hand Eczema: A New Day Is at Hand,” at 7 p.m. ET on March 6 at the Hyatt Regency Orlando ahead of the American Academy of Dermatology (AAD ...

LEO Pharma A/S, a global leader in medical dermatology, today presented late-breaking data showcasing responses in a subgroup of patients from the DELTA 1 and 2 trials at the 83rd American Academy ...

An Ipsos survey commissioned by LEO Pharma Inc. reveals dermatology providers believe there is a lack of awareness and understanding of chronic hand eczema as a condition separate from eczema ...